Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01914484
Title Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto|Novartis
Indications

chronic myeloid leukemia

Therapies

Nilotinib + Ruxolitinib

Age Groups: adult
Covered Countries CAN


No variant requirements are available.